Shuo Y. Yin

No.119 West Nansihuan Road
Beijing, 100070, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Single dose of 5 Gy can damage erythrocytes and consequently induces lymphocyte depletion in spleen and circulating blood.

Single dose of 5 Gy can damage erythrocytes and consequently induces lymphocyte depletion in spleen and circulating blood.

Journal: Frontiers in immunology

Published: April 06, 2026

Advances in diagnosis and treatment of intracranial germ cell tumors and future directions.

Advances in diagnosis and treatment of intracranial germ cell tumors and future directions.

Journal: Critical reviews in oncology/hematology

Published: April 01, 2026

Advances in Pharmacological Therapy for Recurrent High-Grade Meningiomas.

Advances in Pharmacological Therapy for Recurrent High-Grade Meningiomas.

Journal: Current cancer drug targets

Published: January 21, 2026

A machine learning framework predicts oncogenic driver mutations from SNP profiles in lung adenocarcinoma.

A machine learning framework predicts oncogenic driver mutations from SNP profiles in lung adenocarcinoma.

Journal: Discover oncology

Published: September 01, 2025

Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.

Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.

Journal: CNS neuroscience & therapeutics

Published: August 06, 2025

Relationship between cerebral perfusion and cognition in white matter hyperintensities of presumed vascular origin: A prospective 3D-pCASL study.

Relationship between cerebral perfusion and cognition in white matter hyperintensities of presumed vascular origin: A prospective 3D-pCASL study.

Journal: Medicine

Published: February 28, 2025

Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system.

Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system.

Journal: Leukemia & lymphoma

Published: January 17, 2025

The Baseline Pan-Immune‑Inflammation Value (PIV) and PILE in Predicting Clinical Outcomes and Therapeutic Response for Primary Central Nervous System Lymphoma.

The Baseline Pan-Immune‑Inflammation Value (PIV) and PILE in Predicting Clinical Outcomes and Therapeutic Response for Primary Central Nervous System Lymphoma.

Journal: Journal of inflammation research

Published: May 06, 2024

Primary brainstem lymphoma: clinical characteristics, treatment methods, and prognostic factors of 56 patients.

Primary brainstem lymphoma: clinical characteristics, treatment methods, and prognostic factors of 56 patients.

Journal: The oncologist

Published: May 06, 2024

Clinical study on the efficacy and safety of glaucoma drainage implants in the treatment of different types of glaucoma

Clinical study on the efficacy and safety of glaucoma drainage implants in the treatment of different types of glaucoma

Journal: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Published: May 05, 2024

Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases.

Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases.

Journal: Annals of hematology

Published: March 20, 2024

Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma.

Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma.

Journal: Journal of neuro-oncology

Published: February 20, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026